Modern aspects of the therapy of acute respiratory viral infections (systematic review)
https://doi.org/10.22625/2072-6732-2024-16-4-23-31
Abstract
The emergence of new strains of respiratory viruses, especially pandemic ones, resistant to antiviral drugs, dictates the need for further search for new molecules, or reformatting of existing drugs, expanding their indications for use. The use of broadspectrum antivirals or immunomodulators is now well justified. The goal is to systematize published data on the effectiveness and safety of the drug inosine pranobex for acute respiratory viral infections, including influenza and the new coronavirus infection COVID19. The results of in vivo and in vitro studies are summarized, which examine the mechanisms of influence of inosine pranobex on the human immune system and therapeutic effectiveness against a wide range of viral pathogens. The positive results of clinical studies conducted in different countries on ARVI and influenza are briefly described. A promising direction is the use of inosine pranobex in the treatment of COVID19, which has been proven by its use in clinical trials in adults by researchers from different countries and is reflected in our review.
About the Authors
E. V. Esaulenko
Saint-Petersburg State Pediatric Medical University
Russian Federation
Competing Interests:
Russian Federation
Saint-Petersburg
Competing Interests:
none
A. D. Ibrokhimova
Saint-Petersburg State Pediatric Medical University
Russian Federation
Competing Interests:
Russian Federation
Saint-Petersburg
Competing Interests:
none
M. G. Pozdnyakova
Saint-Petersburg State Pediatric Medical University
Russian Federation
Competing Interests:
Russian Federation
Saint-Petersburg
Competing Interests:
none
K. E. Novak
Saint-Petersburg State Pediatric Medical University
Russian Federation
Competing Interests:
Russian Federation
Saint-Petersburg
Competing Interests:
none
References
1. O sostoyanii sanitarno-e’pidemiologicheskogo blagopoluchiya naseleniya v Rossijskoj Federacii v 2023 godu: Gosudarstvennyj doklad. Moskva: Federal’naya sluzhba po nadzoru v sfere zashhity prav potrebitelej i blagopoluchiya cheloveka, 2024. – 364 s.
2. Allen P. Management of common cold symptoms with overthe-counter medications: clearing the confusion / P. Allen, S. Simenson // Postgrad Med. – 2013. – V. 125 №1. – S. 73–811
3. Dunn J.J. Emerging respiratory viruses other than influenza /j.J. Dunn, B. Melissa, M.B. Miller // Clin Lab Med. – 2014. – V. 34 №2. – S.409–430. doi: 10.1016/j.cll.2014.02.011.
4. World Health Organization. Influenza (Seasonal) Key Facts. 2023. [Internet]. [cited 2024 Nov 15]. Available from: https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)
5. Iuliano A.D. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study / A.D. Iuliano, K.M. Roguski, H.H. Chang, D.J. Muscatello, R. Palekar, S. Tempia et al. // Lancet. 2018. – № 391. – R. 1285–1300. doi: https://www.doi.org/10.1016/S0140-6736(17)33293-2.
6. World Health Organization. What is a pandemic? 24 February 2010. [Internet]. [cited 2024 Nov15]. Available from: http://www.who.int/csr/disease/swineflu/frequently_asked_questions/pandemic/en/index.
7. Il’icheva T.N. Dve pandemii XXI veka: COVID-19 i svinoj gripp – 2009» / T.N. Il’icheva // Medicinskaya immunologiya. 2020. – T. 22 № 6. – S. 1035-1044. doi: 10.15789/1563-0625TPO-2048.
8. World Health Organization. Director-General’s opening remarks at the media briefing on COVID-19 – 2020. [Internet]. [cited 2024 Nov 15]. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-atthe-media-briefing-oncovid-19.
9. Huang C. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China / C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J.Xu, et al. // Lancet. 2020. – № 395. – R. 497–506.
10. Tichopád A. Could the new coronavirus have infected humans prior November 2019? / A. Tichopád, L. Pecen, V. Sedlák // PLoS ONE. 2021. – № 16. – e0248255.
11. Moriyama M. Seasonality of respiratory viral infections / M. Moriyama, W.J. Hugentobler, A. Iwasaki // Annu Rev Virol. 2020. – №7. – R. 83–101.
12. Zajcev A.A. Ostrye respiratornye virusnye infekcii: preimushhestva kombinirovannyx preparatov / A.A. Zajcev // Lechashhij vrach. 2008. – №2.– S.78–79.
13. Isakov V.A. E’ffektivnost’ induktorov interferonov v terapii grippa / V.A. Isakov, I.V. Kabolova, G.L. Dneprovskaya, M.K. Erofeeva // V kn.: Sovremennye problemy infekcionnoj patologii cheloveka. Minsk. 2009. – S. 270–274.
14. Gornostaev Yu.A. Immunomoduliruyushhaya terapiya u pacientov s nespecificheskimi infekcionno-vospalitel’nymi processami v legkix /Yu.A. Gornostaev // Consilium Medicum. 2010. – T.12 №11. – S.1–7.
15. Ershov F.I. Lekarstvennye sredstva, primenyaemye pri virusnyx zabolevaniyax. / F.I. Ershov, M.G. Romancov // Rukovodstvo dlya vrachej. M.: GE’OTAR-Media, 2007. – 368s.
16. Gordon P. The antiviral activity of Isoprinosine / P. Gordon, E.R. Brown //Can J Microbiol. 1972. №18. – R.1463–1470.
17. Beran J. Inosine pranobex deserves attention as a potential immunomodulator to achieve early alteration of the COVID-19 disease course /j.Beran, M. Špajdel, J. Slíva // Viruses. 2021. – V.13 №11 – S. 2246. doi:10.3390/v13112246
18. Isakov V.A. Sovremennye vozmozhnosti terapii respiratornyx infekcij / V.A. Isakov, D.V. Isakov, E.A. Alekseeva // Zh. Klinicheskaya farmakologiya i terapiya. 2017. – T. 26 №5. – S. 8–13.
19. World Health Organization. Coronavirus. [Internet]. [cited 2024 Nov 15]. Available from: http://www.who.int/health-topics/coronavirus.
20. Semenenko T. A. Osobennosti e’pidemicheskoj situacii po ostrym respiratornym virusnym infekciyam s uchetom pandemicheskogo rasprostraneniya COVID-19 / T. A. Semenenko, V. G. Akimkin, E. I. Burceva i dr. // E’pidemiologiya i Vakcinoprofilaktika. 2022. T. 21 №4. – S. 4–15.
21. Levina A.S. E’tiologicheskaya struktura zabolevanij u chasto boleyushhix detej v zavisimosti ot vozrasta / A.S. Levina, I.V. Babachenko, N.V. Skripchenko, E.N. Imyanitov // Rossijskij vestnik perinatologii i pediatrii. 2017. – T. 62 № 2. – S.72–77.
22. Eliseeva M.Yu. Vspomogatel’naya immunoterapiya u pacientov s immunodeficitom i chasto boleyushhix detej / M.Yu. Eliseeva, V.N. Carev, K.N. Masixi i dr. // Spravochnik poliklinicheskogo vracha. 2010. – T. 9 – S. 1–8.
23. Isakov. V.A., Sovremennye vozmozhnosti terapii respiratornyx infekcij / V.A. Isakov, D.V. Isakov, E.A. Alekseeva // Zh. Klinicheskaya farmakologiya i terapiya. 2017. – T. 26 № 5. – S. 8–13.
24. Beigel J. Current and future antiviral therapy of severe seasonal and avian influenza /j.Beigel, M. Bray // Antiviral Res. 2008. – T.78 №1. – S.91–102.
25. E’saulenko E.V. E’ffektivnost’ osel’tamivira pri sezonnom i pandemicheskom grippe / E.V. E’saulenko, V.V. Basina, U.E. Kuznecova, M.G. Pozdnyakova, E.A. Bezuglaya, T.V. Bezuglaya // Zh. Klinicheskaya Infektologiya i parazitologiya. 2024. – T. 13 № 1. – S. 5–17.
26. E’saulenko E.V. Gripp v usloviyax pandemii covid-19-vyzov prinimaet baloksavir / E.V. E’saulenko, A.D. Bushmanova, M.G. Pozdnyakova // Spravochnik poliklinicheskogo vracha. 2021. – № 1. – S. 6–12.
27. Beran J. Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, doubleblind study /j.Beran, E. Šalapová, M. Špajde // BMC Infectious Diseases. 2016. – № 16. – R. 648. doi:10.1186/s12879-016-1965-5.
28. Petrova M. Isoprinosine affects serum cytokine levels in healthy adults / M. Petrova, D. Jelev, A. Ivanova, Z. Krastev //j Interferon Cytokine Res. 2010. – V. 30 №4. – R. 223–228.
29. Gu S. X. Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation / S. X. Gu et al. // Nat. Rev. Cardiol. 2021. – №18. – R. 194–209.
30. Li G. Therapeutic strategies for COVID-19: progress and lessons learned / G. Li, R. Hilgenfeld, R. Whitley, E. De Clercq // Nature Reviews Drug Discovery. 2023. – V. 22 – R. 449– 475.
31. Pawelczyk A. Anti-COVID drugs: repurposing existing drugs or search for new complex entities, strategies and perspectives / A. Pawelczyk, L. Zaprutko // Future Med. Chem. 2020. – V.12 №1. – P. 1743-1757. doi:10.4155/fmc-2020-0204.
32. Nerton D. Pereprofilirovanie lekarstvennyx preparatov i pandemiya COVID-19 / D. Nerton // Zh. VOIS. 2020. –№2. – S.22–30.
33. Michael G. Multiscale interactome analysis coupled with off-target drug predictions reveals drug-repurposing candidates for human coronavirus disease / G. Michael, Haotian Cui, Dar’ya S. Redka, et al. // Sci Rep. 2021. – № 11 – e23315. doi: 10.1038/s41598-021-02432-7.
34. Bartovská Z. Data from the first wave of Covid-19 from the Central Military Hospital, Prague, Czech Republic / Z. Bartovská, F. Andrle, O. Beran, M. Zlámal, D. Řezáč, I. Murinova, M. Holub // Epidemiol Mikrobiol Imunol. 2020. – V.69. – № 4. – R.164–171.
35. Jayanthi C. R. Efficacy and Safety of Inosine Pranobex in COVID-19 Patients: A Multicenter Phase 3 Randomized Double-Blind, Placebo-Controlled Trial / C. R. Jayanthi A.K. Swain, R. T. Ganga, D. Halnor, A. Avhad, M. Saif, et al. //j.Advanced Therapeutics. 2022. – V. 5 – R.1–15.
36. Borges M. Estudio experimental: Manejo del metisoprinol en pacientes con COVID-19 / M. Borges, J. Borges, R. Bastidas // Univ. Cienc. Tecnol. 2020. – № 24 – R. 41–50.
37. Fischer F. COVID-19 and the Elderly: Who Cares? / F. Fischer, L. Raiber, C. Boscher // Front Public Health. 2020. – V. 21 №8 – R.151. doi: 10.3389/fpubh.2020.00151.
38. Santoro A. Immunosenescence and inflammaging in the aging process: age-related diseases or longevity? / A. Santoro, E. Bientinesi, D. Monti // Ageing Research Reviews. 2021. – V 71. – R. 101422.
39. Beran J. Inosine pranobex significantly decreased the case-fatality rate among PCR positive elderly with SARS-CoV-2 at three nursing homes in the Czech Republic /j.Beran, M. Špajdel, V. Katzerová, A. Holoušová, J. Malyš, J. Finger Rousková, J. Slíva // Pathogens. 2020. – № 9. – R. 1055.
40. Kennelly S.P. Asymptomatic carriage rates and case fatality of SARS-CoV-2 infection in residents and staff in Irish nursing homes / S.P. Kennelly, A.H. Dyer, C. Noonan, R. Martin, S.M. Kennelly, A. Martin, D. O’Neill, A. Fallon // Age Ageing. 2021. – № 50. – R. 49–54.
Review
For citations:
Esaulenko E.V., Ibrokhimova A.D., Pozdnyakova M.G., Novak K.E. Modern aspects of the therapy of acute respiratory viral infections (systematic review). Journal Infectology. 2024;16(4):23-31. (In Russ.) https://doi.org/10.22625/2072-6732-2024-16-4-23-31
Views:
300
.png)
.png)
Email this article 